Imsidolimab (anti-IL-36 receptor antagonist) did not demonstrate improvement over placebo in the primary endpoint and key secondary endpoints
Imsidolimab was safe and well tolerated with no imsidolimab-related serious or severe adverse events reported
Company to discontinue imsidolimab clinical development in hidradenitis suppurativa
Enrollment ongoing in the imsidolimab GEMINI-1 GPP Phase 3 registrational trial with top-line data anticipated Q4 2023 and the company plans to outlicense imsidolimab prior to potential FDA approval
Company to focus R&D efforts on its novel immune cell modulator pipeline, including its two checkpoint agonists in clinical-stage development, rosnilimab and ANB032
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.